NCT04361630

Recombinant Human Fibroblast Growth Factor-2 (rhFGF-2) In Gingival Recession Defects

Recombinant Human Fibroblast Growth Factor-2 (rhFGF-2) In Absorbable Collagen Membrane With Coronally Advanced Flap In Class I And II Gingival Recession Defects -A Randomized Control Trial

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: SVS Institute of Dental Sciences · Academic / Other
• Sex: All
• Age: 20 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

This study was a single-arm trial to obtain preliminary data on the efficacy of collagen membranes impregnated with recombinant human fibroblast growth factor (rhFGF-2) in the treatment of Miller's class I and class II gingival recessions.

Detailed description

Soft tissues can be regenerated to cover root exposure and a thin biotype can be converted into a thick biotype by using recombinant human growth factor technology. A recent review stated that growth factors could enhance soft tissue regeneration which includes restoration of mucogingival architecture and regeneration of periodontal hard and soft tissues including bone, cementum and periodontal ligament fibers. Fibroblast growth factor-2 (FGF-2), a heparin-binding cytokine with strong angiogenic activity stimulates the proliferation of undifferentiated mesenchymal cells. These functions can be applied in mucogingival surgery as FGF-2 promotes bone and cementum formation and exhibits an increased potential to promote periodontal regeneration in recession defects.

Conditions

• Periodontitis

Interventions

Type	Name	Description
DRUG	FGF 2	Following a standard surgical protocol, rhFGF-2 impregnated membranes will be placed in sites with gingival recession.

Timeline

• Start date: 2019-05-01
• Primary completion: 2019-11-01
• Completion: 2019-12-01
• First posted: 2020-04-24
• Last updated: 2020-05-01

Locations

1 site across 1 country: India